These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17980915)

  • 1. Pneumococcal immunisation in the 21st century.
    Williams C; Masterton R
    J Infect; 2008 Jan; 56(1):13-9. PubMed ID: 17980915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal vaccine and the new child vaccination schedule.
    Bedford H; Lane L
    Nurs Times; 2006 Sep 26-Oct 2; 102(39):44, 46-7. PubMed ID: 17036888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of pneumococcal disease in the United Kingdom--the start of a new era.
    Clarke SC
    J Med Microbiol; 2006 Aug; 55(Pt 8):975-980. PubMed ID: 16849715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood immunisation (1): planned changes to the routine schedule.
    Diggle L
    Community Pract; 2006 Jul; 79(7):231-2. PubMed ID: 16878524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the new pneumococcal conjugate vaccine in the USA.
    Baucher H
    Arch Dis Child; 2000 Nov; 83(5):396. PubMed ID: 11040145
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules.
    Cameron C; Pebody R
    Euro Surveill; 2006 Mar; 11(3):E060302.4. PubMed ID: 16804223
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on the new pneumococcal conjugate vaccine.
    Holland MJ
    Pediatr Ann; 2001 Sep; 30(9):515-6. PubMed ID: 11554259
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme.
    Bergsaker MA; Feiring B
    Euro Surveill; 2006 Feb; 11(2):E060202.5. PubMed ID: 16804205
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia.
    Chen C; Wood JG; Beutels P; Menzies R; MacIntyre CR; Dirmesropian S; Reyes JF; McIntyre P; Newall AT
    Vaccine; 2018 Feb; 36(10):1265-1271. PubMed ID: 29395534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.
    Türel O; Kisa A; McIntosh ED; Bakir M
    Value Health; 2013; 16(5):755-9. PubMed ID: 23947968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pneumococcal vaccines in children: an update].
    Potin M
    Rev Chilena Infectol; 2014 Aug; 31(4):452-6. PubMed ID: 25327199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of pneumococcal disease by vaccines: promises and challenges.
    Poland GA
    Infect Dis Clin North Am; 2001 Mar; 15(1):97-122. PubMed ID: 11301826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.